Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
Identifieur interne : 001367 ( Main/Corpus ); précédent : 001366; suivant : 001368Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
Auteurs : Tian-Min Xu ; Bin Lin ; Cong Chen ; Long-Gen Liu ; Yuan XueSource :
- Virology journal [ 1743-422X ] ; 2020.
English descriptors
- KwdEn :
- Administration, Oral (MeSH), Aged (MeSH), Antibodies, Neutralizing (administration & dosage), Antibodies, Viral (administration & dosage), Betacoronavirus (isolation & purification), Blood Component Transfusion (methods), C-Reactive Protein (metabolism), COVID-19 (MeSH), Coronavirus Infections (blood), Coronavirus Infections (drug therapy), Coronavirus Infections (immunology), Coronavirus Infections (therapy), Coronavirus Infections (virology), Humans (MeSH), Hydroxychloroquine (administration & dosage), Immunization, Passive (methods), Lactic Acid (blood), Leukocyte Count (MeSH), Male (MeSH), Oxyhemoglobins (MeSH), Pandemics (MeSH), Pneumonia, Viral (blood), Pneumonia, Viral (drug therapy), Pneumonia, Viral (therapy), Pneumonia, Viral (virology), SARS-CoV-2 (MeSH), Viral Load (MeSH).
- MESH :
- chemical , administration & dosage : Antibodies, Neutralizing, Antibodies, Viral, Hydroxychloroquine.
- blood : Coronavirus Infections, Lactic Acid, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- immunology : Coronavirus Infections.
- isolation & purification : Betacoronavirus.
- chemical , metabolism : C-Reactive Protein.
- methods : Blood Component Transfusion, Immunization, Passive.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Administration, Oral, Aged, COVID-19, Humans, Leukocyte Count, Male, Oxyhemoglobins, Pandemics, SARS-CoV-2, Viral Load.
Abstract
BACKGROUND
Convalescent plasma (CP) transfusion was reported to be effective in treating critically ill patients with COVID-19, and hydroxychloroquine could potently inhibit SARS-CoV-2 in vitro. Herein, we reported a case receiving combination therapy with CP transfusion and hydroxychloroquine for the first time.
CASE PRESENTATION
Laboratory findings showed high lactic acid level (2.1 mmol/L) and C-reactive protein (CRP, 48.8 mg/L), and low white blood cell count (1.96 × 10
CONCLUSION
These findings suggested that the effectiveness of combination therapy with CP and hydroxychloroquine may be non-optimal, and specific therapy needs to be explored.
DOI: 10.1186/s12985-020-01354-6
PubMed: 32560646
PubMed Central: PMC7303939
Links to Exploration step
pubmed:32560646Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.</title><author><name sortKey="Xu, Tian Min" sort="Xu, Tian Min" uniqKey="Xu T" first="Tian-Min" last="Xu">Tian-Min Xu</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Third People's Hospital of Changzhou, Changzhou, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Bin" sort="Lin, Bin" uniqKey="Lin B" first="Bin" last="Lin">Bin Lin</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the First People's Hospital of Jintan, Changzhou, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Cong" sort="Chen, Cong" uniqKey="Chen C" first="Cong" last="Chen">Cong Chen</name><affiliation><nlm:affiliation>Changzhou Center for Disease Control and Prevention, Changzhou, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Long Gen" sort="Liu, Long Gen" uniqKey="Liu L" first="Long-Gen" last="Liu">Long-Gen Liu</name><affiliation><nlm:affiliation>Institute of Hepatology, the Third People's Hospital of Changzhou, No. 300 Lanling North Road, Changzhou, 213000, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xue, Yuan" sort="Xue, Yuan" uniqKey="Xue Y" first="Yuan" last="Xue">Yuan Xue</name><affiliation><nlm:affiliation>Institute of Hepatology, the Third People's Hospital of Changzhou, No. 300 Lanling North Road, Changzhou, 213000, Jiangsu, China. xueyuan80908@163.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32560646</idno><idno type="pmid">32560646</idno><idno type="doi">10.1186/s12985-020-01354-6</idno><idno type="pmc">PMC7303939</idno><idno type="wicri:Area/Main/Corpus">001367</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001367</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.</title><author><name sortKey="Xu, Tian Min" sort="Xu, Tian Min" uniqKey="Xu T" first="Tian-Min" last="Xu">Tian-Min Xu</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the Third People's Hospital of Changzhou, Changzhou, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lin, Bin" sort="Lin, Bin" uniqKey="Lin B" first="Bin" last="Lin">Bin Lin</name><affiliation><nlm:affiliation>Department of Infectious Diseases, the First People's Hospital of Jintan, Changzhou, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Chen, Cong" sort="Chen, Cong" uniqKey="Chen C" first="Cong" last="Chen">Cong Chen</name><affiliation><nlm:affiliation>Changzhou Center for Disease Control and Prevention, Changzhou, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Liu, Long Gen" sort="Liu, Long Gen" uniqKey="Liu L" first="Long-Gen" last="Liu">Long-Gen Liu</name><affiliation><nlm:affiliation>Institute of Hepatology, the Third People's Hospital of Changzhou, No. 300 Lanling North Road, Changzhou, 213000, Jiangsu, China.</nlm:affiliation></affiliation></author><author><name sortKey="Xue, Yuan" sort="Xue, Yuan" uniqKey="Xue Y" first="Yuan" last="Xue">Yuan Xue</name><affiliation><nlm:affiliation>Institute of Hepatology, the Third People's Hospital of Changzhou, No. 300 Lanling North Road, Changzhou, 213000, Jiangsu, China. xueyuan80908@163.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Virology journal</title><idno type="eISSN">1743-422X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral (MeSH)</term><term>Aged (MeSH)</term><term>Antibodies, Neutralizing (administration & dosage)</term><term>Antibodies, Viral (administration & dosage)</term><term>Betacoronavirus (isolation & purification)</term><term>Blood Component Transfusion (methods)</term><term>C-Reactive Protein (metabolism)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (blood)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Immunization, Passive (methods)</term><term>Lactic Acid (blood)</term><term>Leukocyte Count (MeSH)</term><term>Male (MeSH)</term><term>Oxyhemoglobins (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (blood)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (therapy)</term><term>Pneumonia, Viral (virology)</term><term>SARS-CoV-2 (MeSH)</term><term>Viral Load (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Coronavirus Infections</term><term>Lactic Acid</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>C-Reactive Protein</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Blood Component Transfusion</term><term>Immunization, Passive</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>COVID-19</term><term>Humans</term><term>Leukocyte Count</term><term>Male</term><term>Oxyhemoglobins</term><term>Pandemics</term><term>SARS-CoV-2</term><term>Viral Load</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Convalescent plasma (CP) transfusion was reported to be effective in treating critically ill patients with COVID-19, and hydroxychloroquine could potently inhibit SARS-CoV-2 in vitro. Herein, we reported a case receiving combination therapy with CP transfusion and hydroxychloroquine for the first time.</p></div><div type="abstract" xml:lang="en"><p><b>CASE PRESENTATION</b></p><p>Laboratory findings showed high lactic acid level (2.1 mmol/L) and C-reactive protein (CRP, 48.8 mg/L), and low white blood cell count (1.96 × 10</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>These findings suggested that the effectiveness of combination therapy with CP and hydroxychloroquine may be non-optimal, and specific therapy needs to be explored.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32560646</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>06</Month><Day>19</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.</ArticleTitle><Pagination><MedlinePgn>80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-020-01354-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">Convalescent plasma (CP) transfusion was reported to be effective in treating critically ill patients with COVID-19, and hydroxychloroquine could potently inhibit SARS-CoV-2 in vitro. Herein, we reported a case receiving combination therapy with CP transfusion and hydroxychloroquine for the first time.</AbstractText><AbstractText Label="CASE PRESENTATION">Laboratory findings showed high lactic acid level (2.1 mmol/L) and C-reactive protein (CRP, 48.8 mg/L), and low white blood cell count (1.96 × 10<sup>9</sup>/L) in a 65-year-old Chinese man, who was diagnosed with severe COVID-19. CP was intravenously given twice, and hydroxychloroquine was orally administrated for a week (0.2 g, three times a day). The lactic acid and C-reactive protein levels remained high (2.1 mmol/L and 73.23 mg/L, respectively), while the arterial oxyhemoglobin saturation decreased to 86% with a low oxygenation index (OI, 76 mmHg) on day 4 after CP transfusion. His temperature returned to normal and the OI ascended above 300 on day 11. Moreover, the RNA test remained positive in throat swab, and computed tomography revealed severe pulmonary lesions on day 11 after admission.</AbstractText><AbstractText Label="CONCLUSION">These findings suggested that the effectiveness of combination therapy with CP and hydroxychloroquine may be non-optimal, and specific therapy needs to be explored.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Tian-Min</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the Third People's Hospital of Changzhou, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, the First People's Hospital of Jintan, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Cong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Changzhou Center for Disease Control and Prevention, Changzhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Long-Gen</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Institute of Hepatology, the Third People's Hospital of Changzhou, No. 300 Lanling North Road, Changzhou, 213000, Jiangsu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5428-0058</Identifier><AffiliationInfo><Affiliation>Institute of Hepatology, the Third People's Hospital of Changzhou, No. 300 Lanling North Road, Changzhou, 213000, Jiangsu, China. xueyuan80908@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>BK20180183</GrantID><Agency>Natural Science Foundation of Jiangsu Province</Agency><Country>International</Country></Grant><Grant><GrantID>KJ201925</GrantID><Agency>Science and Technology Project of Jintan</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010108">Oxyhemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016913" MajorTopicYN="N">Blood Component Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010108" MajorTopicYN="N">Oxyhemoglobins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Convalescent plasma</Keyword><Keyword MajorTopicYN="Y">Cycle threshold</Keyword><Keyword MajorTopicYN="Y">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32560646</ArticleId><ArticleId IdType="doi">10.1186/s12985-020-01354-6</ArticleId><ArticleId IdType="pii">10.1186/s12985-020-01354-6</ArticleId><ArticleId IdType="pmc">PMC7303939</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chest. 2020 Mar 31;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32243945</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496</Citation><ArticleIdList><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation><ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2020 Jun 16;222(1):38-43</Citation><ArticleIdList><ArticleId IdType="pubmed">32348485</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001367 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001367 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32560646
|texte= Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32560646" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |